The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period. Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668